To further validate our findings and assess the clinical relevance of PRMT-1, -4, -6, and -8 in chemotherapy resistance, we analyzed patient data from the Cancer Treatment Response Gene Signature Database (CTR-DB), a publicly available resource. This evidence concerns the gene PRMT1 and cancer.